|29th September 2015
Strategic Planning is a core capability at Blue Latitude. We work across many different therapy areas, helping our clients to position, launch, and support their brands through the full product lifecycle. For many years, pharma have reduced the impact of loss of exclusivity (LOE) by launching alternative molecules to treat the same condition. Whilst the commercial intention of this is to maximise the value gained from a therapy area, the execution of a portfolio strategy can impact this if done poorly. With Pharma in the midst of a patent cliff, portfolios of treatments are becoming more and more common, and the need for a clear co-positioning strategy has never been greater. A large client of ours recently approached us to understand how they could maximise the value of their gastroenterology portfolio. For several years, they had been focused on supporting one blockbuster brand with great success. However, with the impact of LOE fast approaching, it was vital that they widen their view to consider other brands in the pipeline, and how the portfolio would deliver value as a whole. Head of Brand Strategy Jenna Earl talks us through the three most important things to understand about portfolio positioning in pharma.
When you have a portfolio that includes multiple brands with overlapping patient groups, positioning requires an additional dimension; positioning of the portfolio as well as of the individual brands. If portfolio brands are positioned in a silo, it creates unnecessary competition between the brands, and ultimately, creates confusion for prescribers and payers. ...
|27th August 2020
Precision and personalised medicines are more than products, they are services in their own right. So, how should pharma approach this uncharted territory to ensure targeted therapies work for patients?
|28th July 2020
At the beginning of the COVID-19 Pandemic, Senior Account Executive Lauren Fernandes took a course at the London School of Hygiene and Tropical Medicine to better understand how the global response to the virus and to ensure we were best positioned to serve our clients during this challenging time. She shares the key learnings and why understanding the epidemiology of the disease is integral for fighting it.
|14th July 2020
Blue Latitude Health, and our parent company Fishawack Health, have developed exclusive intellectual property, processes and tools to ensure you’re engaging customers in the right way. View our service one-pagers below to find out how we can help solve your challenges whether you’re in a medical, brand, portfolio or an above brand role.